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expression in early and longstanding arthritis
Abstract
OBJECTIVE: To analyze the expression, regulation, and biologic relevance of Toll-like receptors
(TLRs) 1-10 in synovial and skin fibroblasts and to determine the expression levels of TLRs 2, 3, and 4
in synovial tissues from patients with early rheumatoid arthritis (RA), longstanding RA, and
osteoarthritis (OA). METHODS: Expression of TLRs 1-10 in RA synovial fibroblasts (RASFs), OASFs,
and skin fibroblasts was analyzed by real-time polymerase chain reaction (PCR). Fibroblasts were
stimulated with tumor necrosis factor alpha, interleukin-1beta (IL-1beta), bacterial lipopeptide,
poly(I-C), lipopolysaccharide, and flagellin. Production of IL-6 was determined by enzyme-linked
immunosorbent assay and induction of TLRs 2-5, matrix metalloproteinases (MMPs) 3 and 13
messenger RNA by real-time PCR. Expression of TLRs 2-4 in synovial tissues was analyzed by
immunohistochemistry. RESULTS: Synovial fibroblasts expressed TLRs 1-6, but not TLRs 7-10.
Among the expressed TLRs, TLR-3 and TLR-4 were the most abundant in synovial fibroblasts, and
stimulation of synovial fibroblasts with the TLR-3 ligand poly(I-C) led to the most pronounced increase
in IL-6, MMP-3, and MMP-13. In contrast, skin fibroblasts did not up-regulate MMP-3 or MMP-13
after stimulation with any of the tested stimuli. In synovial tissues from patients with early RA, TLR-3
and TLR-4 were highly expressed and were comparable to the levels of patients with longstanding RA.
These expression levels were elevated as compared with those in OA. CONCLUSION: Our findings of
high expression of TLRs, particularly TLRs 3 and 4, at an early stage of RA and the reactivity of
synovial fibroblasts in vitro to TLR ligands suggest that TLR signaling pathways resulting in persistent
inflammation and joint destruction are activated early in the disease process.
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ABSTRACT: 
 
Objective: To analyze the expression, regulation and biological relevance of Toll-like 
receptors (TLRs) 1-10 in synovial and skin fibroblasts. Furthermore to determine the 
expression levels of TLR2, 3 and 4 in synovial tissues of patients with early rheumatoid 
arthritis (RA), longstanding RA and osteoarthritis (OA). 
Methods: Expression of TLR1-10 in RA synovial fibroblasts (SF), OASF and skin fibroblasts 
was analyzed by Real-time-PCR. Fibroblasts were stimulated with TNF-α, IL-1β, bLP, 
poly(I-C), LPS and flagellin. The production of IL-6 was determined by ELISA and the 
induction of TLR2-5, matrix metalloproteinase (MMP)3 and MMP13 mRNA by Real-time-
PCR. The expression of TLR2-4 in synovial tissues was analyzed by immunohistochemistry. 
Results: SF express TLR1, 2, 3, 4, 5 and 6 but no TLR7, 8, 9, 10. Among the expressed 
TLRs, TLR3 and TLR4 were the most abundant in SF, and stimulation of SF with the TLR3 
ligand poly(I-C) led to the most pronounced increase of IL-6, MMP3 and MMP13. In 
contrast, skin fibroblasts did neither upregulate MMP3 nor MMP13 after stimulation with any 
of the tested stimuli. In synovial tissues of patients with early RA, TLR3 and TLR4 were 
highly expressed and comparable to patients with longstanding arthritis. The expression levels 
were elevated when compared to OA.  
Conclusion: Our findings of high expression of TLRs, in particular TLR3 and 4, at an early 
stage of RA and the reactivity of synovial fibroblasts in vitro to TLR ligands suggest that TLR 
signaling pathways resulting in persistent inflammation and joint destruction are activated 
already in early disease. 
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Introduction 
Rheumatoid arthritis (RA) is a systemic inflammatory disease leading to joint destruction, 
deformity and loss of function. Persistent synovial inflammation is one of the most 
characteristic features of RA and can already be observed at an early stage of the disease (1). 
Also, in the majority of RA patients, erosions develop during the first 2 years of onset (2). 
Therefore focusing on the very early phase of RA may increase the chance to stop the disease 
in order to prevent irreversible disability.  
In the inflammatory and matrix degrading processes that characterize joint destruction in RA, 
RA synovial fibroblasts (RASF) have been found to take an active part. RASF, together with 
synovial macrophages, are the main cell types in the hyperplastic synovial lining layer and at 
sites of invasion into cartilage and bone. Activated RASF secrete a wide panel of pro-
inflammatory cytokines, chemokines and matrix-degrading enzymes, which perpetuate the 
chronic inflammation and lead to progressive, irreversible damage of the diseased joint (3). 
Among the pro-inflammatory cytokines present at high levels in the inflamed joints, TNF-α is 
considered as main activating stimulus for RASF.  
In recent years, it has been shown that RASF can also be strongly stimulated by activation of 
Toll-like receptor (TLR) pathways (4). TLRs belong to the family of pattern recognition 
receptors and play a crucial role in the activation of the innate immune system in response to 
invading microorganisms. According to their corresponding ligands, TLRs can be categorized 
in two main groups: TLRs 1, 2, 4 and 6 are receptors for lipid-based pathogen-associated 
molecular patterns (PAMPs) while TLRs 3, 7, 8 and 9 are receptors for nucleic acid–based 
PAMPs. Besides the main categories, TLR5 represents the receptor for flagellin, the major 
structural protein of the flagella of gram-negative bacteria [4]. The ligand for TLR10 is not 
known up to now. TLR2 ligands are the most diverse group among all TLR ligands due to the 
heterodimerization of TLR2 with either TLR1 or TLR6. TLR signaling leads to the 
upregulation of costimulatory molecules by antigen presenting cells and therefore facilitates 
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the subsequent activation of the adaptive immune responses via the provision of the second 
signal to T cell stimulation. In joints of patients with RA exogenous and endogenous TLR 
ligands, such as peptidoglycan (PGN) and necrotic cells, have been identified (5, 6). The 
finding that activation of innate immunity via TLRs is connected to activation of the adaptive 
immune system, in addition to the identification of endogenous ligands for certain TLRs 
strengthened the hypothesis that an early dysfunction of TLR pathways might result in 
autoimmune inflammation in joints (7).  
In previous studies, we and others could show that TLR2, 3 and 4 are expressed in the 
synovium of patients with longstanding RA. Stimulation of the TLR2 pathway in RASF leads 
to translocation of nuclear factor-κB, secretion of pro-inflammatory cytokines and matrix 
metalloproteinases (MMPs), and to the expression of various chemokines (6, 8-11). Likewise, 
stimulation of TLR3 and TLR4 pathways by synthetic or endogenous ligands induced the 
production of interferon β, IL-6 and the chemokines CXCL10 and CCL5 (5).  
In the present study we comprehensively analyzed TLR expression, regulation and 
functionality in RASF and RA tissue at different stages of the disease as well as in skin 
fibroblasts. First we established an expression profile of the currently known human TLRs 1-
10 in synovial and skin fibroblasts. Then we compared induced expression of the most 
abundantly expressed TLRs after various stimuli and their functionality in transmitting the 
production of disease-related molecules by RASF. To complete our analysis, we quantified 
and compared the expression of TLRs in the synovium of RA patients at early and late stage 
of the disease and of patients with osteoarthritis (OA).  
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MATERIAL AND METHODS: 
 
Patients and tissue preparation: Synovial tissues were taken from trauma patients and RA 
and OA patients undergoing joint replacement surgery. Synovial samples of RA patients with 
onset of disease <12 months (early RA) were taken by blind needle biopsy. All RA patients 
fulfilled the American College of Rheumatology criteria for the classification of RA (12). OA 
was diagnosed according to clinical features. The characteristics of the RA and OA patients 
are shown in Table 1. 
For cell culture, tissues were minced and digested in 150 mg/ml dispase II (Roche, 
Mannheim, Germany) for 1h at 37°C. Synovial fibroblasts were grown in DMEM (Gibco 
Invitrogen, Basel, Switzerland) supplemented with 10% fetal calf serum, 50 IU/ml penicillin-
streptomycin, 2 mM L-glutamine, 10 mM HEPES, and 0.2% fungicide (all Gibco Invitrogen). 
Cell cultures were maintained in a 5% CO2 humidified incubator at 37°C. Cultured synovial 
fibroblasts were used for experiments after 4 to 9 passages. For immunohistochemistry, 
tissues were embedded in Tissue-Tek® Oct compound (Sakura Finetek, Zoeterwoude, The 
Netherlands), snap frozen in liquid nitrogen and stored at -80° C until further use.  
  
Immunohistochemistry: Frozen sections (5 µm) of synovial tissues were thawed, fixed with 
acetone for 10 min and air-dried. After washing in phosphate buffered saline (PBS) 
endogenous peroxidase was blocked with 0.3% H2O2 for 10 min. The slides were blocked 
with 1% bovine serum albumin/5% horse serum for one hour and incubated with the 
respective primary antibodies or isotype controls for 1h at room temperature or overnight at 
4°C. After washing with PBS/0.05% Tween® slides were incubated with the respective 
secondary antibodies for 30 min. In slides incubated with biotinylated secondary antibodies 
the signal was amplified with horseradish-peroxidase (HRP)-conjugated streptavidin 
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(Vectastain Elite ABC kit, Vector laboratories, Burlingame, CA). All sections were developed 
with aminoethylcarbazole chromogen and counterstained with hematoxylin.  
Primary antibodies: polyclonal goat anti-human TLR2 (2 µg/ml), polyclonal rabbit anti-
human TLR3 (1 µg/ml), polyclonal rabbit anti-human TLR4 (1 µg/ml) (all Santa Cruz 
Biotechnology, Santa Cruz, CA), monoclonal mouse anti-human CD68 (2 µg/ml; DAKO)  
Secondary antibodies were biotinylated mouse anti-goat and mouse anti-rabbit IgGs, HRP-
conjugated goat anti-mouse IgGs (all Jackson Technologies). 
Two observers who were blinded to the source of the tissues quantified the expression of each 
antigen semiquantitatively on a 5-point scale, where0 = no staining,  1 = weak expression, 
single cells stained,   2 = mild expression, limited areas stained  3 = moderate expression, 
weak overall expression or extended areas stained,  4 = strong expression, strong overall 
staining).  
  
 
Stimulation experiments: Synovial fibroblasts were seeded in 6-well plates at a density of 
1x105/well. After 24h, cells were stimulated with 10 ng/ml TNFα, 1 ng/ml IL-1β (both R&D 
Systems, Minneapolis, MN), 300 ng/ml bacterial lipopeptide (bLP) palmitoyl-3-cysteine-
serine-lysine-4, 10 µg/ml polyI-C (both InvivoGen, San Diego, CA),  100 ng/ml 
lipopolysaccaride (LPS) from Escherichia coli J5 (List Biological Laboratories, Campbell, 
CA) or 100ng/ml flagellin from S. thyphimurium (Invivogen). After 24h of stimulation, 
supernatants were collected and cells were lysed in RLT buffer. Total RNA was isolated using 
the RNeasy MiniPrep kit (Qiagen, Basel, Switzerland) including DNase treatment. 
 
Real-time PCR: Complementary DNA (cDNA) was generated by reverse transcription of 
total RNA using random hexamers and multiscribe reverse transcriptase (both Applied 
Biosystems, Rotkreuz, Switzerland). As negative controls non reverse transcribed samples 
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were used. For quantification of mRNA levels, single-reporter Real-time PCR was performed 
using the ABI Prism 7700 Sequence Detection system (Applied Biosystems, Rotkreuz, 
Switzerland). Eukaryotic 18S rRNA levels, measured with a pre-developed primer/probe 
system (Applied Biosystems, Rotkreuz, Switzerland), served as endogenous control for 
relative quantification. The difference between the values of comparative threshold cycles (Ct) 
of the tested gene and 18S (dCt) was used to calculate changes of relative expression (ddCt) 
after stimulation following the formula ddCt = dCt (sample stimulated) - dCt (sample 
unstimulated). x-fold regulation was calculated using the expression 2-ddCt. Only samples with 
a difference of at least 4 cycles between cDNA and non reverse transcribed RNA samples 
were considered for calculations. 
Primers were designed with Primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and synthesized by Microsynth (Balgach, Switzerland). 
Dissociation curve analysis for each SYBR green primer pair and reaction was performed to 
verify specific amplification. Primer sequences (forward primer; reverse primer; probe) can 
be found in the Supplementary Table I. 
 
Enzyme linked immunoabsorbant assay (ELISA): IL-6 and TNFα were detected by ELISA 
with OptEIA® Kits (BD Pharmingen, San Diego, CA). 
 
Statistical analysis: Values are presented as mean ± SEM. Mann-Whitney U test or 
Wilcoxon signed rank test were applied to analyze results for significance (p<0.05) or 
Spearman’s rank for correlation using GraphPad Prism Software. 
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RESULTS: 
 
Expression of TLRs 1-10 mRNA in SF and skin fibroblasts. In previous reports we and 
others have shown that TLR2, 3 and 4 are expressed in RASF. However, since no expression 
profile of all known human TLRs (TLR1-10) has been established so far in synovial or skin 
fibroblasts, we measured levels of mRNA for TLR1-10 using relative quantification Real-
time PCR in RASF, OASF, normal SF (NSF) and skin fibroblasts (Figure 1A). The highest 
mRNA expression was found for TLR3, followed by TLR4. From the TLR2 subfamily, 
mRNA for TLR2, 1 and 6 was readily detected, whereas mRNA for TLR10 could not be 
detected. The mRNA levels of TLR5 were only just above the detection limit, which was set 
at a minimum of 4 cycles difference between cDNA and control. mRNA from members of the 
TLR9 subfamily (TLR7, 8, 9) was not detectable in unstimulated fibroblasts and could also 
not be induced by various stimuli (data not shown). TLR2 mRNA levels showed the highest 
variability of all TLRs. No significant differences in the expression of the various TLRs were 
found between RASF, OASF, NSF and skin fibroblasts. However, there was a trend of higher 
TLR2 and -3 mRNA levels in RASF..  
To see whether the basal expression of TLR2, 3, 4 and 5 can be enhanced in RASF, we 
stimulated the cells for 24h with the pro-inflammatory cytokines TNFα and IL-1β, and the 
TLR ligands bLP, polyI-C, LPS and flagellin respectively. The expression of TLR2 was 
significantly induced by all of the tested stimuli except for flagellin (Figure 1B). In contrast, 
the expression of TLR3 was only significantly upregulated after stimulation with polyI-C or 
LPS, whereas bLP, flagellin, TNFα or IL-1β had no effect. The expression of TLR4 and 
TLR5 was not significantly changed by any of the used stimuli.  
 
Production of pro-inflammatory and matrix-degrading enzymes after stimulation with 
TLR ligands. Since we found that in synovial and skin fibroblasts TLR2, 3, 4 and 5 are 
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expressed, we analyzed whether they differ in their property to transmit activation in these 
cells. First we treated synovial and skin fibroblasts for 24h with various concentrations of 
TLR2, 3, 4 and 5 ligands and measured the production of the pro-inflammatory cytokine IL-6. 
The TLR3 ligand polyI-C as well as LPS, bLP and flagellin induced the production of IL-6 in 
RASF. Saturation for TLR2 and TLR5 by bLP and flagellin respectively was almost reached 
at the lowest concentration used. Increasing TLR2 stimulation only lead to a further slight 
increase until 300ng/ml. In contrast, the activation of TLR3 and TLR4 showed a clear dose 
response with a maximum at 20ug/ml and 200ng/ml respectively. At comparable 
concentrations LPS induced the highest level of IL-6 (100ng/ml: 79.8 pg/ml IL-6), followed 
by bLP (150ng/ml: 34.7 pg/ml IL-6) and flagellin (100ng/ml: 24pg/ml IL-6). When 
comparing the concentrations at 50% of maximal stimulation, PIC induced the highest levels 
of IL-6 (Figure 2A). In accordance to the lack of TLR7, 8 and 9 expression, stimulation of 
synovial fibroblasts with TLR7, 8 and 9 ligands did not induce IL-6 production (data not 
shown). Skin fibroblasts also upregulated the production of IL-6 after stimulation with TLR 
ligands, but the amount was markedly less when compared to RASF for all tested stimuli 
(Figure 2B). No significant difference in the upregulation of IL-6 after TLR stimulation was 
seen between RASF and OASF, nevertheless, a trend towards reduced levels of IL-6 in 
supernatants of OASF cultures was observed (data not shown). Measurements of TNFα 
showed no detectable levels of TNFα in the supernatants of RASF stimulated with bLP, PIC, 
LPS or flagellin (data not shown). 
Since a hallmark of RASF activation is the production of matrix-degrading enzymes, we then 
measured the expression of the matrix-metalloproteinases MMP3 and MMP13 after 
stimulation with TLR ligands. PolyI-C induced the expression of MMP3 mRNA 191 ± 93 
fold and of MMP13 mRNA 98 ± 16 fold  (mean ± SEM, Figure 2C). bLP, LPS and flagellin 
also significantly induced MMP expression in RASF. OASF reacted similarly to TLR 
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stimulation as RASF (data not shown). Conversely, in skin fibroblasts the expression of 
mRNA for MMP3 or MMP13 was not significantly changed after stimulation. 
 
Expression of TLR2, 3 and 4 at different stages of RA compared to OA. To assess 
whether the activation of TLRs is an early event in the pathogenesis of RA, we compared the 
expression of TLRs in synovial tissues of patients at a very early stage of the disease (<12 
months) and in tissues of patients with longstanding RA. Snap frozen synovial tissue sections 
of patients with early RA (n=10), longstanding RA (n=11) and OA (n=11) were stained for 
TLR2, 3 and 4. For each antigen the intensity of expression was assessed with an expression 
score as described in the Methods. TLR2, 3 and 4 were present in the synovium of early RA 
patients and were expressed to the same extent as in patients with longstanding RA (Figure 3). 
TLR3 and 4 were significantly higher expressed in early and late RA patients compared to 
OA patients. The levels of TLR2 did not differ between RA and OA samples. In addition, the 
expression of TLR3 and 4 was clearly more abundant than the expression of TLR2. All three 
analyzed TLRs were primarily expressed in the lining layer, but extended to cells in the 
sublining and perivascular areas in samples with more abundant expression. Furthermore, a 
comparison with the staining intensity of CD68 showed that the expression of TLRs was not 
connected to the number of macrophages in the synovium (data not shown).  
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DISCUSSION: 
The aim of our study was to comprehensively assess the expression and function of TLRs in 
synovial and skin fibroblasts. In addition, to define whether activation of TLR signaling may 
be an early event in the pathogenesis of RA, we comparatively analyzed the expression of 
TLRs in synovial tissues in early and late stages of disease.  
Comparable to the synovium, TLRs are expressed on a variety of cell types found in the skin, 
including keratinocytes and Langerhans cells in the epidermis. Keratinocytes constitutively 
express mRNA for TLR1, 2, 3, 4, 5, 6, 9 and 10 but not TLR7 and 8 (13). We found that skin 
fibroblasts constitutively express mRNA for TLR1, 2, 3, 4, 5 and 6 but not for TLR7, 8, 9 and 
10. These data indicate that also skin fibroblasts might play a role in the defense against 
invading pathogens as they express functional TLRs. In a previous report Kim et al. 
demonstrated significantly higher TLR2 and TLR4 mRNA levels in RASF compared to 
OASF (14). In contrast to this report we show only a trend of higher TLR2 and TLR3 
expression in RASF compared to OASF, NSF and skin fibroblasts, not reaching statistical 
significance. However, even though the levels of constitutive TLR mRNA expression did not 
significantly differ between synovial and skin fibroblasts, activation of these cells with 
PAMPs resulted in differential expression patterns of proinflammatory cytokines and matrix 
degrading enzymes. In particular, RA synovial fibroblasts produced significantly higher 
amounts of IL-6, MMP3 and MMP13. Since it has been demonstrated that in pathological 
conditions, skin fibroblasts appear to be more prone to produce matrix instead of matrix 
degrading enzymes, it does not appear to be surprising that skin fibroblasts react differently to 
stimuli than synovial fibroblasts (15, 16). Taken together, these data point to the importance 
of fibroblasts as sentinel cells of the innate immune response and their capability to react to 
PAMPs with different effector molecules according to the needs of the tissues they are part of.  
Furthermore, we show that synovial fibroblasts derived from trauma, RA or OA patients 
constitutively express mRNA for TLR1, 2, 3, 4, 5 and 6 but not for TLR7, 8, 9 and 10. 
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Among the TLR mRNA expressed in synovial fibroblasts TLR3 and TLR4 mRNA was the 
most abundant, followed by members of the TLR2 subfamily. Constitutive expression of 
TLR9 has mainly been reported in plasmacytoid dendritic cells and B-cells, but also 
keratinocytes, pulmonary and intestinal epithelial cells have been shown to express TLR9 (13, 
17-19). In contrast, mRNA for TLR9 was not detectable in synovial nor in skin fibroblasts. 
The lack of TLR9 mRNA expression excludes activation of synovial fibroblasts by DNA or 
single-stranded RNA via TLRs, as we already showed in an earlier study for CpG 
oligodeoxynucleotides (6). Our finding is also in accordance with several studies in other 
tissues confirming TLR3 as the main nucleic acid-specific TLR in non-immune cells (5, 20-
22). Similarly, the expression of TLR2 and TLR4 in RA synovial fibroblast has also been 
documented in earlier reports (6, 8, 23, 24). Our study is now adding TLR5 to the TLR 
expression profile in synovial fibroblasts.  
In accordance with the basal expression pattern in cultured synovial fibroblasts, TLR3 and 
TLR4 were also the most abundant of the measured TLRs in the synovium. Of particular 
interest is the finding that already at an early stage of the disease the expression of TLR3 and 
TLR4 is elevated in the synovium when compared to OA patients. This result suggests that 
overexpression of TLRs is an early event and that their levels do not change over the course 
of the disease. Since TLRs can be induced within hours as demonstrated in the in vitro 
experiments, we cannot rule out upregulation of TLRs as a secondary event in the course of 
the development of the joint inflammation. However, the fact that the levels of TLRs in early 
RA synovial tissue are clearly higher than in OA demonstrates that activation of TLR 
pathways is not a late event restricted only to severe destructive stages of disease.  Induction 
of TLRs may be due to unspecific triggering infections at early stages of disease or due to the 
presence of endogenous ligands. In addition genetic background, epigenetic changes, or 
environmental factors like smoking might play a role in this over-expression. 
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At the present, it can only be speculated whether there is a functional reason for the increased 
expression of specific TLRs. Based on previous data, it might be hypothesized that the 
availability of endogenous ligands might determine which TLRs are upregulated (5, 25).  
In contrast to our data, a previous study reported slightly higher expression of TLR2 than 
TLR4 in RA synovium (10). Reasons for this discrepancy might be differences in the patient 
cohorts or in the methods used.  Furthermore, it has to be acknowledged that expression of 
TLRs is not specific for RA and was found in a wide variety of inflammatory diseases such as 
psoriasis, inflammatory bowel disease and systemic lupus erythematodes (26-28). Of note, 
despite the differences in DMARD therapy between the patients with early and longstanding 
RA the expression of TLRs 3 and 4 was not significantly different in these two patient 
populations.  
Several exogenous pathogens as triggers of RA have been proposed, however so far no 
specific microorganism associated with RA was identified. Nonetheless, in the course of 
infection, bacterial or viral products may be deposited in the joints and lead to activation of 
synovial cells via TLR (29). In addition, TLR activation by endogenous ligands has been 
reported. As examples hyaluronan, fibrin, heat shock proteins were shown to activate TLR4 
(25, 30-33). We previously demonstrated that dsRNA released from necrotic cells stimulates 
synovial fibroblasts in a TLR3 dependent fashion (5). Since these endogenous ligands are 
present in elevated amounts in inflamed joints, TLR expression levels and responsiveness to 
TLR ligands of synovial cells are critical factors. Here we demonstrate that TLRs 3 and 4 are 
highly expressed in the synovium already at early disease stages as well as in long standing 
disease. Together with the demonstration that RASF stimulated in vitro with TLR3 and 4 
ligands produce a wide range of proinflammatory cytokines, chemokines and tissue 
destructive enzymes, our data suggests that stimulation of TLR pathways occurs early in 
disease resulting in synovial fibroblasts activation contributing to development of synovial 
inflammation and joint destruction.      
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TABLES: 
 
Table 1. Patients characteristics 
 
 
  age* 
(years) 
sex  
(f/m) 
Disease dur# 
(years) 
NSAIDs DMARDs RF pos     
(>20 I.U.) 
CRP† 
(mg/l) 
RA n=11 64.55 
(40 - 79) 
10/1 21.8 
(8 - 41) 
3/11 10/11 
5/11 + steroid 
2/11 + antiTNF 
8/11 20.3 
(2.4 - 121) 
(3 NA) 
early RA n=10 61.9 
(41 - 76) 
6/4 0.4 
(0.16 - 1) 
9/10 0/10 7/9 (1 NA) 32.3 
(11 - 106) 
OA n=11 75.64* 
(64 - 84) 
6/5 NA 1/11 0/11 NA NA 
 
* OA patients were significantly older than RA/early RA patients. 
# Disease duration was significantly longer in RA compared to early RA patients. 
† CRP levels were significantly higher in early RA compared to RA patients. 
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 FIGURE LEGENDS:  
 
Figure 1: 
(A) Basal mRNA expression levels for TLRs 1-6 in RASF (n=8), OASF (n=6), NSF (n=3) 
and skin fibroblasts (n=4). Lines within the boxes represent the median, boxes represent the 
25th and 50th percentiles, lines outside the boxes correspond to the minimum and maximum 
values. (B) Induction of mRNA for TLRs 2, 3 and 4 in RASF (n=6) by pro-inflammatory 
cytokines and TLR ligands. Baseline expression was set as 1, all values shown are means ± 
SEM, significant differences from baseline were calculated by Wilcoxon signed rank test. 
 
Figure 2:  
A) Dose dependent stimulation of IL-6 production by bLP, LPS and poly (I-C) (n=4). B) 
Production of IL-6 protein by untreated and TLR ligand stimulated RASF (n=9) and skin 
fibroblasts (n=4). C) Induction of mRNA for MMP3 and MMP13 by TLR ligands in RASF 
(n=6) and skin fibroblasts (n=3). Baseline expression was set as 1, all values shown are means 
± SEM.  
 
Figure 3:  
A) Representative sections of synovial tissues of patients with early RA, longstanding RA or 
OA, stained for TLR2, TLR3 or TLR4. As a negative control, sections were treated with 
respective isotype immunoglobulines. All sections were counterstained with hematoxylin, 
positive signals appear in red, original magnification x 200. B) The quantity of TLR2, TLR3 
and TLR4 expression in synovial tissues of patients with early RA (n=10), longstanding RA 
(n=11) and OA (n=11) was assessed with an expression score (0=no staining, 1=weak 
staining, 2=mild staining, 3=moderate staining, 4=strong staining).  
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 Supplementatry Table I: 
TLR1: CAGTGTCTGGTACACGCATGGT; TTTCAAAAACCGTGTCTGTTAAGAGA; 
TGCCCATCCAAAATTAGCCCGTTCC. TLR2: GGCCAGCAAATTACCTGTGTG; 
AGGCGGACATCCTGAACCT; TCCATCCCATGTGCGTGGCC. TLR3: 
CCTGGTTTGTTAATTGGATTAACGA; TGAGGTGGAGTGTTGCAAAGG; 
ACCCATACCAACATCCCTGAGCTGTCAA. TLR4: 
CAGAGTTTCCTGCAATGGATCA; GCTTATCTGAAGGTGTTGCACAT; 
CGTTCAACTTCCACCAAGAGCTGCCT. TLR5: TGCCTTGAAGCCTTCAGTTATG; 
CCAACCACCACCATGATGAG; CCAGGGCAGGTGCTTATCTGACCTTAACA. TLR6: 
GAAGAAGAACAACCCTTTAGGATAGC; AGGCAAACAAAATGGAAGCTT; 
TGCAACATCATGACCAAAGACAAAGAACCT. TLR7: 
TTTACCTGGATGGAAACCAGCTA; TCAAGGCTGAGAAGCTGTAAGCTA; 
AGAGATACCGCAGGGCCTCCCG. TLR8: TTATGTGTTCCAGGAACTCAGAGAA; 
TAATACCCAAGTTGATAGTCGATAAGTTTG; TGATTTCCAGCCCCTGATGCAGC. 
TLR9: GGACCTCTGGTACTGCTTCCA; AAGCTCGTTGTACACCCAGTCT; 
ACGATGCCTTCGTGGTCTTCGACAAA. TLR10 (SYBR primer): 
CTGATGACCAACTGCTCCAA; AGTCTGCGGGAACCTTTCTT. MMP-3, 
GGGCCATCAGAGGAAATGAG, CACGGTTGGAGGGAAACCTA, 
AGCTGGATACCCAAGAGGCATCCACAC. MMP13 TCCTACAAATCTCGCGGGAAT, 
GCATTTCTCGGAGCCTCTCA, CATGGAGCTTGCTGCATTCTCCTTCAG 
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